EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oncogenic snoRNA SNORD78 fuels colorectal cancer by protecting the m 6 A reader IMP2 to enhance phospholipid metabolism

Yingqi Zhao iD, Xiaoyun Hu, Yalun Li iD, Jing Zhang, Hao Guo, Yuying Zhang iD, Ting Wu, Jinyu Guo, Yi Peng, Ying Che iD, Xianglong Zhu, Qiuchen Chen und 3 weitere

Proceedings of the National Academy of Sciences · 21.07.2026 · 123 (29)

DOI: 10.1073/pnas.2531283123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.07.2026. Verfasst von Yingqi Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, The People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Phospholipids, RNA, Small Nucleolar. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation ().

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small nucleolar RNAs (snoRNAs) play crucial regulatory roles in various cancers. However, the mechanisms by which snoRNAs regulate N6-methyladenosine (m 6 A) modifications in colorectal cancer (CRC) remain unclear. This study systematically deciphered the precise interaction mechanism between SNORD78 and the m 6 A reader IMP2 in CRC. We demonstrate that SNORD78 specifically stabilizes IMP2 to activate the PIK3CD-CHKA-Kennedy pathway in an m 6 A-dependent manner, promoting endoplasmic reticulum stress (ERS) and phosphatidylcholine (PC) biosynthesis, thereby driving CRC. Conversely, the SNORD78 -targeting antisense oligonucleotide (ASO), ASO-78, effectively suppresses ERS and PC levels, inhibiting CRC progression. Mechanistically, SNORD78 , relying on the “UAAUGA” element in its C-D box region, specifically binds to the Lys221 ubiquitination site of IMP2, blocking TRIM25-mediated degradation of IMP2 and maintaining its stability. IMP2 enhanced the stability and translation of the target mRNAs PIK3CD and CHKA by recognizing their corresponding m 6 A positions, m 6 A-3208 and m 6 A-1619, respectively, to reshape the phosphatidylcholine metabolite profile in CRC cells. In terms of potential therapeutic strategies, the ASO-78 can significantly inhibit CRC cell proliferation, reduce ERS levels, and decrease phosphatidylcholine content. The combination of ASO-78 and IMP2 inhibitor IMP2-IN1, by dual blocking of the SNORD78 –IMP2 axis, exhibits an excellent proliferation-inhibiting effect in CRC organoids. This study not only reveals a mechanism by which the SNORD78 –IMP2 interaction regulates CRC occurrence and development but also provides theoretical basis for innovative therapeutic strategies for precise targeting of tumor snoRNA-m 6 A reader interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGene Expression Regulation, NeoplasticPhospholipidsRNA, Small NucleolarRNA-Binding ProteinsAnimalsHumansMiceCase-Control StudiesHT29 CellsMice, Inbred BALB CMice, NudeRNA MethylationUbiquitinationMolecular Targeted TherapyOligonucleotides, AntisenseCholine KinaseClass I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

IMP2SNORD78antisense oligonucleotidem6Aphosphatidylcholine

Substanzen

CHKA protein, humanIGF2BP2 protein, humanPhospholipidsPIK3CD protein, humanRNA, Small NucleolarRNA-Binding ProteinsOligonucleotides, AntisenseCholine KinaseClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, Liaoning, The People's Republic of China.
  • Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment o…
  • Department of Anorectal Surgery, First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, The People's Republic of China.
  • Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7AE, United Kingdom.

ORCID-Profile: Yingqi Zhao, Yalun Li, Yuying Zhang, Ying Che, Huizhe Wu

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • China Postdoctoral Science Foundation ()

Zitieren

APA

Zhao, Y., Hu, X., Li, Y., Zhang, J., Guo, H., Zhang, Y., Wu, T., Guo, J., Peng, Y., Che, Y., Zhu, X., Chen, Q., Grieve, D., Wei, M., & Wu, H. (2026). Oncogenic snoRNA SNORD78 fuels colorectal cancer by protecting the m 6 A reader IMP2 to enhance phospholipid metabolism. Proceedings of the National Academy of Sciences, 123(29). https://doi.org/10.1073/pnas.2531283123

Vancouver

Zhao Y, Hu X, Li Y, Zhang J, Guo H, Zhang Y, et al. Oncogenic snoRNA SNORD78 fuels colorectal cancer by protecting the m 6 A reader IMP2 to enhance phospholipid metabolism. Proceedings of the National Academy of Sciences. 2026;123(29). doi:10.1073/pnas.2531283123

BibTeX
@article{Zhao2026,
  author = {Zhao, Yingqi and Hu, Xiaoyun and Li, Yalun and Zhang, Jing and Guo, Hao and Zhang, Yuying and Wu, Ting and Guo, Jinyu and Peng, Yi and Che, Ying and Zhu, Xianglong and Chen, Qiuchen and Grieve, David and Wei, Minjie and Wu, Huizhe},
  title = {Oncogenic snoRNA SNORD78 fuels colorectal cancer by protecting the m 6 A reader IMP2 to enhance phospholipid metabolism},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {29},
  doi = {10.1073/pnas.2531283123}
}
Kostenlos starten →